Beam Therapeutics
29.78
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children’s Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Trade GPT
Similar Stocks
© Rockalpha Limited. Todos los Derechos Reservados.
Rockalpha Limited está inscrita en el Registro de Proveedores de Servicios Financieros de Nueva Zelanda (FSP: 1001454). El registro de Proveedores de Servicios Financieros de Rockalpha Limited puede verificarse en el Registro de Proveedores de Servicios Financieros. Rockalpha Limited es miembro del Insurance & Financial Services Ombudsman Scheme, un proveedor independiente de servicios de resolución de disputas. Rockalpha Limited no está autorizada por ningún organismo regulador neozelandés para prestar servicios monetarios o inmobiliarios a clientes, y la inscripción de Rockalpha Limited en el registro neozelandés de proveedores de servicios financieros o su pertenencia al Insurance & Financial Services Ombudsman Scheme no significa que Rockalpha Limited esté sujeta a la regulación o supervisión activa de un organismo regulador neozelandés.Rockalpha Limited está inscrita en el Registro de Proveedores de Servicios Financieros de Nueva Zelanda (FSP: 1001454). El registro de Proveedores de Servicios Financieros de Rockalpha Limited puede verificarse en el Registro de Proveedores de Servicios Financieros. Rockalpha Limited es miembro del Insurance & Financial Services Ombudsman Scheme, un proveedor independiente de servicios de resolución de conflictos.